EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population‐Based Cohort Study

Huilin Tang, Ying Lu, Michael S Okun, William T Donahoo, Adolfo Ramirez-Zamora, Fei Wang, Yu Huang, Melissa Armstrong iD, Mikael Svensson, Beth A Virnig, Steven T DeKosky, Jiang Bian und 1 weitere

Movement Disorders · 2024-11 · 39 (11) · 1960-1970

DOI: 10.1002/mds.29992 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Movement Disorders, online erschienen am 27.08.2024. Verfasst von Huilin Tang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Parkinson Disease, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Medicare. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, American Foundation for Pharmaceutical Education, Pharmaceutical Research and Manufacturers of America Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Previous studies have suggested that glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) may have a disease‐modifying effect in the development of Parkinson's disease (PD), but population studies yielded inconsistent results.

Objective

The aim was to compare the risk of PD associated with GLP‐1RAs compared to dipeptidyl peptidase 4 inhibitors (DPP4i) among older adults with type 2 diabetes (T2D).

Methods

Using U.S. Medicare administrative data from 2016 to 2020, we conducted a population‐based cohort study comparing the new use of GLP‐1RA with the new use of DPP4i among adults aged ≥66 years with T2D. The primary endpoint was a new diagnosis of PD. A stabilized inverse probability of treatment weighting (sIPTW)–adjusted Cox proportional hazards regression model was employed to estimate the hazard ratio (HR) and 95% confidence intervals (CI) for PD between GLP‐1RA and DPP4i users.

Results

This study included 89,074 Medicare beneficiaries who initiated either GLP‐1RA (n = 30,091) or DPP4i (n = 58,983). The crude incidence rate of PD was lower among GLP‐1RA users than DPP4i users (2.85 vs. 3.92 patients per 1000 person‐years). An sIPTW‐adjusted Cox model showed that GLP‐1RA users were associated with a 23% lower risk of PD than DPP4i users (HR, 0.77; 95% CI, 0.63–0.95). Our findings were largely consistent across different subgroup analyses such as sex, race, and molecular structure of GLP‐1RA.

Conclusion

Among Medicare beneficiaries with T2D, the new use of GLP‐1RAs was significantly associated with a decreased risk of PD compared to the new use of DPP4i. © 2024 International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsMedicareGlucagon-Like Peptide-1 Receptor AgonistsHumansMaleAgedFemaleCohort StudiesAged, 80 and overUnited StatesHypoglycemic Agents

Stichwörter der Autor:innen

Parkinson's diseasedipeptidyl peptidase 4 inhibitor (DPP4i)glucagon‐like peptide‐1 receptor agonist (GLP‐1RA)type 2 diabetes

Substanzen

Dipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, Florida, USA.
  • Department of Neurology, Norman Fixel Institute for Neurological Diseases, University of Florida College of Medicine, Gainesville, Florida, USA.
  • Division of Endocrinology, Diabetes and Metabolism, College of Medicine, University of Florida, Gainesville, Florida, USA.
  • Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA.
  • Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, Florida, USA.
  • Center for Drug Evaluation and Safety, University of Florida, Gainesville, Florida, USA.

ORCID-Profile: Melissa Armstrong

Förderung

  • NIDDK NIH HHS
  • American Foundation for Pharmaceutical Education
  • Pharmaceutical Research and Manufacturers of America Foundation
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Tang, H., Lu, Y., Okun, M. S., Donahoo, W. T., Ramirez-Zamora, A., Wang, F., Huang, Y., Armstrong, M., Svensson, M., Virnig, B. A., DeKosky, S. T., Bian, J., & Guo, J. (2024). Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population‐Based Cohort Study. Movement Disorders, 39(11), 1960-1970. https://doi.org/10.1002/mds.29992

Vancouver

Tang H, Lu Y, Okun MS, Donahoo WT, Ramirez-Zamora A, Wang F, et al. Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population‐Based Cohort Study. Movement Disorders. 2024;39(11):1960-1970. doi:10.1002/mds.29992

BibTeX
@article{Tang2024,
  author = {Tang, Huilin and Lu, Ying and Okun, Michael S and Donahoo, William T and Ramirez-Zamora, Adolfo and Wang, Fei and Huang, Yu and Armstrong, Melissa and Svensson, Mikael and Virnig, Beth A and DeKosky, Steven T and Bian, Jiang and Guo, Jingchuan},
  title = {Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population‐Based Cohort Study},
  journal = {Movement Disorders},
  year = {2024},
  volume = {39},
  number = {11},
  pages = {1960--1970},
  doi = {10.1002/mds.29992}
}
Kostenlos starten →